Monitoring of blood cyclosporine concentration in steroid-resistant nephrotic syndrome

Internal Medicine

Volumn 47, Issue 18, 2008, Pages 1567-1572

  Naito, Masayo ^a   Takei, Takashi ^a   Eguchi, Aya ^a   Uchida, Keiko ^a   Tsuchiya, Ken ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Absorption profile; Cyclosporine; Nephrotic syndrome; Preprandial administration; Proteinuria

Indexed keywords

CREATININE; CYCLOSPORIN; NITROGEN; PREDNISOLONE; STEROID; UREA;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PROTEINURIA; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; EATING; EMULSIONS; FEMALE; HUMANS; MALE; NEPHROTIC SYNDROME; PROTEINURIA;

EID: 56349087822     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.1088     Document Type: Article

References (20)

1. Meyrier A, Noel LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int 45: 1446-1456, 1994.
2. Iida HNT, Sakai N, Aoki S. Effect of cyclosporin therapy on idiopathic membranous nephropathy presented with refractory nephrotic syndrome. Clin Exp Nephro1 4: 81-85, 2000.
3. Matsumoto H, Nakao T, Okada T, et al. Initial remission-inducing effect of very low-dose cyclosporin monotherapy for minimal-change nephrotic syndrome in Japanese adults. Clin Nephrol 55: 143-148, 2001.
4. Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 59: 1484-1490, 2001.
5. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 68: 1356-1361, 1999.
6. Kung L, Batiuk TD, Palomo-Pinon S, Noujaim J, Helms LM, Halloran PF. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am J Transplant 1: 325-333, 2001.
7. Primmett DR, Levine M, Kovarik JM, Mueller EA, Keown PA. Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure. Ther Drug Monit 20: 276-283, 1998.
8. Schadeli F, Marti HP, Frey FJ, Uehlinger DE. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients. Clin Pharmacokinet 41: 59-69, 2002.
9. Cole E, Maham N, Cardella C, et al. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation 75: 2086-2090, 2003.
10. Einecke G, Mai I, Fritsche L, et al. Cyclosporin C2-hour monitoring after renal transplantation. Int J Clin Pharmacol Ther 41: 477-481, 2003.
11. Kusaba T, Konno Y, Hatta S, et al. More stable and reliable pharmacokinetics with preprandial administration of cyclosporine compared with postprandial administration in patients with refractory nephrotic syndrome. Pharmacotherapy 25: 52-58, 2005.
12. Mraz W, Muller C, Molnar B, Knedel M. Analysis of cyclosporin A (CsA) concentrations by fluorescence polarization immunoassay (FPIA): comparison with radio immunoassay (RIA) and liquid chromatography (HPLC). Transplant Proc 21 (1 pt l): 885-887, 1989.
13. Dalere GM, Lum BL, Cooney GF, Wong-Chin M. Comparison of three methods for cyclosporine area under the curve monitoring calculations. Ther Drug Monit 17: 305-307, 1995.
14. Uchida K, Tominaga Y, Haba T, et al. Usefulness of two-point AUC (0-4) monitoring in maintenance renal transplant patients. Transplant Proc 33: 3128-3130, 2001.
15. Belitsky P, Dunn S, Johnston A, Levy G. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. Clin Pharmacokinet 39: 117-125, 2000.
16. Mahalati K, Belitsky P, West K, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 12: 828-833, 2001.
17. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (neora1) during the first 2 weeks after renal transplantation. Transplantation 72: 1024-1032, 2001.
18. Internation Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2: 157-166, 2002.
19. Hulzebos CV, Wolters H, Plosch T, et al. Cyclosporin and enterohepatic circulation of bile salts in rats: decreased cholate synthesis but increased intestinal reabsorption. J Pharmacol Exp Ther 304: 356-363, 2003.
20. Takeda A, Horike K, Onoda H, et al. Benefits of cyclosporine absorption profiling in nephrotic syndrome: Preprandial once-daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profile. Nephrology 12: 197-204, 2007.